"BIO-RESORT: Ultrathin-strut DES Beneficial in Small Vessels at Three Years" - Erik Swain
Patients with small coronary vessels had a lower rate of target lesion revascularization if they were implanted with an ultrathin-strut sirolimus-eluting stent compared with a thin-strut zotarolimus-eluting stent, according to new data published in JAMA Cardiology. The analysis included 1,452 patients who had at least one small-vessel lesion and available three-year follow-up data. Roxana Mehran, MD, director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai said that the study “supports the hypothesis that the comparative contribution of stent strut thickness may be greatest among vessels that are not adequately sized to tolerate thicker-stent struts with the greater degree of intimal hyperplasia that may result from these devices.”
— Roxana Mehran, MD, Director, Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Weiner Cardiovascular Institute, Professor, Medicine, Cardiology, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai